What is the appropriate approach to evaluating and managing a 14-year-old with suspected growth hormone deficiency?

Approach to a 14-Year-Old with Suspected Growth Hormone Deficiency

Evaluate this adolescent with a systematic auxological assessment, biochemical testing including IGF-I and IGFBP-3, bone age determination, and pituitary MRI, followed by GH provocation testing if initial workup supports GHD—but recognize that at age 14, you must act quickly as the window for growth intervention is closing rapidly.

Initial Clinical Assessment

Focus your history and physical examination on these specific elements:

• Growth velocity: Calculate current growth rate and compare to age-appropriate standards. Growth deceleration is more significant than absolute height 1
• Pubertal status: Assess Tanner staging carefully—delayed puberty can mask or mimic GHD
• Neonatal history: Look for hypoglycemia, micropenis (males), or prolonged jaundice suggesting congenital GHD 1
• Midparental height: Calculate target height to determine if current height represents pathologic deviation
• Body composition: GHD typically presents with increased adiposity, particularly truncal 1
• Syndromic features: Screen for Turner syndrome, Noonan syndrome, or SHOX haploinsufficiency 2

Diagnostic Workup Algorithm

Step 1: Auxological Measurements

• Plot height, weight, and BMI on updated national growth references
• Calculate height standard deviation score (SDS)
• Document growth velocity over 6-12 months if available 1, 3

Step 2: Bone Age Assessment

• Obtain left hand and wrist radiograph
• Delayed bone age supports GHD diagnosis and indicates remaining growth potential 3
• Critical at age 14: If bone age is advanced, growth window may be nearly closed

Step 3: Biochemical Screening

• IGF-I and IGFBP-3: Measure and compare to age- and sex-specific reference ranges 1
• Low IGF-I supports GHD but normal levels do not exclude it
• Thyroid function tests (TSH, free T4): Hypothyroidism must be excluded
• Morning cortisol: Screen for multiple pituitary hormone deficiencies (MPHD)
• Celiac screening and complete metabolic panel to exclude systemic causes

Step 4: Pituitary MRI

• Obtain MRI before provocation testing 1
• Look for:
  • Pituitary hypoplasia or aplasia
  • Ectopic posterior pituitary (EPP)
  • Stalk abnormalities
  • Structural lesions (craniopharyngioma, germinoma)
• If structural lesion or proven genetic cause is found, GH provocation testing is NOT required 4

Step 5: GH Provocation Testing

Only proceed if initial workup supports GHD and no structural lesion identified:

• Two different stimulation tests are recommended 5, 4
• Common tests include:
  • Insulin tolerance test (ITT)—gold standard but requires careful monitoring for hypoglycemia
  • Glucagon stimulation test
  • Arginine stimulation test
  • Clonidine stimulation test
• Diagnostic cutoff: Peak GH <7-10 ng/mL indicates GHD 5, 6
• Important caveat: Cutoff values are somewhat arbitrary, and there is significant variability in clinical practice 6

Critical Considerations at Age 14

Time is of the essence. At 14 years old, this patient is approaching or may be in mid-to-late puberty:

• Assess pubertal stage immediately: If Tanner stage 4-5, epiphyseal closure may be imminent
• Bone age is critical: If bone age >14 years in males or >13 years in females, growth potential is severely limited
• Consider GnRH analogue therapy to delay puberty and extend growth window if GHD is confirmed and significant growth potential remains 7

Management Based on Diagnosis

If GHD Confirmed:

Initiate recombinant human GH (rhGH) therapy promptly 7, 5:

• Starting dose: 0.025 mg/kg/day (approximately 0.16-0.24 mg/kg/week divided into daily injections) 7
• Adjust dose every 3 months based on:
  • Growth velocity response
  • IGF-I levels (target mid-normal range for age/sex)
  • Clinical tolerance 3

If Isolated Idiopathic GHD:

• High likelihood of normal GH secretion after puberty 8
• Plan for retesting after completion of linear growth
• Patients with isolated idiopathic GHD often do not require lifelong replacement 8

If Multiple Pituitary Hormone Deficiencies (MPHD):

• Replace other deficient hormones first (thyroid, cortisol) before starting GH
• No need for retesting in adulthood—these patients have permanent GHD 4, 8
• Plan for transition to adult endocrinology care

Common Pitfalls to Avoid

1. Delaying evaluation: At age 14, every month matters for growth potential
2. Missing hypothyroidism: Must be corrected before GH testing or treatment
3. Overlooking obesity: BMI affects GH response to stimulation testing—obese patients may have falsely low GH peaks 9
4. Assuming normal IGF-I excludes GHD: IGF-I has limited sensitivity for GHD diagnosis 1
5. Failing to obtain MRI: Structural lesions change management completely
6. Not considering pubertal delay treatment: May need sex steroid priming or GnRH analogue therapy depending on pubertal status 7

Monitoring During Treatment

• Height and growth velocity: Every 3 months
• IGF-I levels: Every 3-6 months to guide dosing 3
• Bone age: Annually to assess remaining growth potential
• Glucose metabolism: Monitor for insulin resistance, particularly if risk factors present 1
• Thyroid function: GH can unmask central hypothyroidism

Transition Planning

If GHD persists after linear growth completion 8:

• Retesting required for isolated idiopathic GHD (high rate of normalization)
• No retesting needed if: MPHD, structural lesion, or genetic cause
• Continue GH replacement until peak bone mass achieved (typically age 25-30 years) if persistent GHD confirmed 8